Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 3.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 586,063 shares of the medical device company’s stock after buying an additional 18,874 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Tandem Diabetes Care were worth $24,855,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Assetmark Inc. acquired a new position in Tandem Diabetes Care in the 3rd quarter valued at about $29,000. ORG Wealth Partners LLC purchased a new stake in Tandem Diabetes Care in the 3rd quarter valued at about $30,000. ORG Partners LLC purchased a new stake in Tandem Diabetes Care in the 2nd quarter valued at about $31,000. Waldron Private Wealth LLC purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth about $50,000. Finally, Headlands Technologies LLC grew its holdings in shares of Tandem Diabetes Care by 110.0% during the 2nd quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company’s stock worth $83,000 after purchasing an additional 1,079 shares during the period.

Insider Buying and Selling

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. This trade represents a 4.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target for the company. The Goldman Sachs Group began coverage on Tandem Diabetes Care in a research report on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price on the stock. Morgan Stanley raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a research report on Monday. Canaccord Genuity Group dropped their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Canaccord Genuity Group assumed coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $54.25.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $30.27 on Friday. The business’s 50-day moving average price is $33.85 and its 200 day moving average price is $40.41. The firm has a market cap of $1.99 billion, a P/E ratio of -15.68 and a beta of 1.32. Tandem Diabetes Care, Inc. has a 52-week low of $21.07 and a 52-week high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. The firm had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. Tandem Diabetes Care’s revenue was up 31.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.38) earnings per share. As a group, sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.